- Home
- PAVM vs IMRN Comparison
PAVM vs IMRN Comparison
Compare PAVM & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- IMRN
- Stock Information
- Founded
- PAVM 2014
- IMRN 1994
- Country
- PAVM United States
- IMRN Australia
- Employees
- PAVM N/A
- IMRN N/A
- Industry
- PAVM Medical/Dental Instruments
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- IMRN Health Care
- Exchange
- PAVM Nasdaq
- IMRN Nasdaq
- Market Cap
- PAVM 8.0M
- IMRN 9.2M
- IPO Year
- PAVM 2016
- IMRN N/A
- Fundamental
- Price
- PAVM $0.46
- IMRN $1.75
- Analyst Decision
- PAVM Strong Buy
- IMRN Strong Buy
- Analyst Count
- PAVM 1
- IMRN 1
- Target Price
- PAVM $19.00
- IMRN $5.00
- AVG Volume (30 Days)
- PAVM 250.8K
- IMRN 668.8K
- Earning Date
- PAVM 08-14-2025
- IMRN 09-08-2025
- Dividend Yield
- PAVM N/A
- IMRN N/A
- EPS Growth
- PAVM N/A
- IMRN N/A
- EPS
- PAVM 0.96
- IMRN N/A
- Revenue
- PAVM $1,993,000.00
- IMRN $4,048,286.00
- Revenue This Year
- PAVM N/A
- IMRN N/A
- Revenue Next Year
- PAVM $455.63
- IMRN N/A
- P/E Ratio
- PAVM $0.48
- IMRN N/A
- Revenue Growth
- PAVM N/A
- IMRN 82.90
- 52 Week Low
- PAVM $0.30
- IMRN $1.50
- 52 Week High
- PAVM $1.90
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- PAVM 35.35
- IMRN 45.75
- Support Level
- PAVM $0.43
- IMRN $1.57
- Resistance Level
- PAVM $0.53
- IMRN $1.76
- Average True Range (ATR)
- PAVM 0.05
- IMRN 0.07
- MACD
- PAVM -0.01
- IMRN 0.00
- Stochastic Oscillator
- PAVM 52.70
- IMRN 47.79
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.